TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: change in extension range of motion (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AFC of the operated ovary
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Recurrences of endometriomas
Endpoint domain: Adverse events/effects
Primary endpoint: WBC, CRP, IL-6, TNF-alpha, TC, TG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Sensitivity of ST for detecting POTS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of ST for detecting NCS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention of patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in skin retraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction in blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Attenuation values in the coronary arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Latency period until a reaction appeared
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Scores on the patch test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: NAA/(Cho+Cr) ratio in lentiform nucleus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: MAC value of sevoflurane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ED₅₀ of sevoflurane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ED₉₅ of sevoflurane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: corticospinal excitability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: short-interval intracortical inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Scheduled checks completion rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to detection of generator and lead problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of PVT episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of MVT episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Return of spontaneous circulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean volume of bladder treated to doses above 60 Gy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean clinical target volume treated to 95% of prescribed dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prostate-specific antigen levels at 3 and 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gains in dorsal NME
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reductions in pain after NME testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adrenal insufficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Doses of norepinephrine required to maintain cerebral perfusion pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bioequivalence of Zevin® and Zovirax®
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of cardiac events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Resource use during the first six months
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total NASA-TLX score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Frustration level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Muscle power in the injured leg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mother-to-child transmission (MTCT) of HIV
Endpoint domain: Mortality/survival
Primary endpoint: Maternal HIV RNA viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maternal anaemia (haematocrit <33%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction in the risk of suicidal behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nucleated red blood cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: perfusion of the microcirculation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in brain amyloid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Increased serum Aβ1‐42
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Elevated triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quality of Death-1 (QOD-1) scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: increased diuresis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: improved cardiac output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: improved PaO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: response inhibition on the emotional Go/NoGo-task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: recognition of briefly presented facial expressions of negative valence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Effective dose (ED)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Radiation exposure outcomes
Primary endpoint: illness absenteeism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percent change in HDL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean percent change in LDL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum LDL-C concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 7β-OH-campesterol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 7-keto-campesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glenohumeral joint laxity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Joint position sense
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Handballing accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-h glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cesarean delivery rate for fetal distress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Admission rate to neonatal intensive care unit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reaction times of alertness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective feeling of fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Death or moderate-to-severe disability
Endpoint domain: Mortality/survival
Primary endpoint: Survival free of a new major cardiovascular event
Endpoint domain: Mortality/survival
Primary endpoint: ischemic episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Physiological stability measured by the SCRIP score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor activity level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relief of perineal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to depressive relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severity of illness status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fine motor performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in urinary levels of [TIMP2] × [IGFBP7]
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: VAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: SF-MPQ
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Peak VO₂ (ml/kg/min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Food cue-evoked brain activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: PLD clearance variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prolongation of QTc-interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: acute limb ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: primary composite end point
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: proportion of patients relapsed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients with 12-week confirmed disability progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reappearance of menstruation at 6 months after chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Time to restoration of menstruation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Ovarian reserve measured by inhibin B and anti-Müllerian hormone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Recovery of MMSE scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of POCD
Endpoint domain: Adverse events/effects
Primary endpoint: Electromyographic activity of studied muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analgesic benefit at 60 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target IOP achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Detection of health risk behaviours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk for STI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unplanned pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Reduction of anger level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in symptoms of somatization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in symptoms of anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relief of chemosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relief of itching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: physician's impression score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FT4 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Anti-TPO positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: change from baseline daily morning PEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: mean percent change in breast density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of VCAM-1 and E-selectin in HUVECs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lag time of LDL from the Mediterranean diet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: coronary event rates
Endpoint domain: Mortality/survival
Primary endpoint: Duration of severe neutropenia (ANC < 500/microL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Duration of ANC less than 1,000/microL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean FAC dose-intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of infants colonized with Lactobacillus and Bifidobacterium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced limb edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: onset of weekly smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: time-weighted average decline in RSV viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: progression to LRTC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Willingness to participate again
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PA2024-specific T-cell proliferation responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Development of a PA2024-specific humoral response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time-to-PSA progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Plasma TF activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Quality of life (SGRQ score)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean weight change from end of treatment to follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants with a global EDE score within normal range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants recovered using stringent criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: absolute inflammatory lesion count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: absolute non-inflammatory lesion count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: percent inflammatory lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction in ALT, AST, gamma‐GT, CK, and LDH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunisation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: joint control improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient progress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary composite cardiac event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: better outcome on IIP
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: maxillary growth restriction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mandibular retrusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative extent of absorption of coumarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effective refractory period of the accessory pathway
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Shortest cycle length of the atrioventricular node
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative incidence of eczema at 2 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cumulative incidence of asthma at 5 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: homeostatic model of assessment-insulin resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: 1-year rates of death
Endpoint domain: Mortality/survival
Primary endpoint: severe heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Return on Investment (ROI)
Endpoint domain: Resource use
Primary endpoint: Absenteeism
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: PaO2/FiO2 ratio on the first day after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: SLE Disease Activity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prednisone administration
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Duration of capillary flowstop reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptom and medication scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mRNA levels of TGF‐β and IL‐10
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall judgment of periorbital appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient satisfaction with recovery and outcome
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total monthly costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: incidence of colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rates of full immunisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose-normalized pitavastatin AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose-normalized pitavastatin C(max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete absence of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical cure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: MACISO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: experimental pain sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endothelium-dependent vasodilation of the radial artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: LDL-cholesterol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: Median reduction of tumor on pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Polysensitisation to multiple allergens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HbA1c level <7%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cholesterol/HDL ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Risk of severe exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asthma control days
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: voluntary UE movement recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: spasticity reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UE function and daily function recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average side-to-side difference in MPE in ACL-insufficient group
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: First attempt success rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mortality of patients with MELD scores from 30 to 39
Endpoint domain: Mortality/survival
Primary endpoint: mean percentage of reticulocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative volume of the carpal tunnel and median nerve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: melanoma-specific survival
Endpoint domain: Mortality/survival
Primary endpoint: lymphedema incidence
Endpoint domain: Adverse events/effects